MARKET

IMRNW

IMRNW

IMMURON
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4300
+0.0050
+1.18%
Closed 16:00 01/14 EST
OPEN
0.4300
PREV CLOSE
0.4250
HIGH
0.4300
LOW
0.4300
VOLUME
1.52K
TURNOVER
--
52 WEEK HIGH
1.990
52 WEEK LOW
0.3022
MARKET CAP
--
P/E (TTM)
-15.0877
1D
5D
1M
3M
1Y
5Y
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pat...
GlobeNewswire · 3d ago
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to support the Travelan clinical development effortTotal Award ...
GlobeNewswire · 4d ago
BRIEF-Immuron Ltd - USU Have Initiated Manufacturing Campaign To Produce First Batches Of Investigational Medical Products In Nov 2021
reuters.com · 11/15/2021 11:08
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC products in Travelers’ Diarrhea initiatedUSU are anticipat...
GlobeNewswire · 11/15/2021 11:00
US DoD Naval Medical Research Center Clinical Update
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration (FDA) planned for Q1 CY2022 to support Two human phase II ...
GlobeNewswire · 11/10/2021 11:00
BRIEF-Immuron Ltd Imm-124E Demonstrates Antiviral T-Cell Immunity
reuters.com · 10/08/2021 10:03
Companies Like Immuron (ASX:IMC) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 09/25/2021 00:40
Immuron Director resignation
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pat...
GlobeNewswire · 09/24/2021 03:00
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMRNW. Analyze the recent business situations of IMMURON through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
No Data
About IMRNW
Immuron Limited is an Australia-based biopharmaceutical company. The Company is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The Company operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The Company's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The Company focused on clinical development of three drug candidates and several in early-stage preclinical development.

Webull offers kinds of Immuron Ltd stock information, including NASDAQ:IMRNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRNW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRNW stock methods without spending real money on the virtual paper trading platform.